Search the Newsreel

Ocular Therapeutix Options for New Hires Carry $8.40 Price

Ocular Therapeutix (NASDAQ: OCUL) has granted inducement equity awards to eight new non-executive employees, including stock options for up to 53,975 shares and restricted stock units for 17,450 shares, effective August 3, 2026. The stock options have an exercise price of $8.40 per share, …

Oculis Holding earnings beat by CHF0.23, revenue topped estimates

Oculis Holding reported second-quarter earnings that surpassed analyst estimates by CHF0.23, with revenue also exceeding expectations at CHF311.14K against a consensus of CHF157.82K. Despite the positive earnings surprise, the company's stock price has seen a significant decline, down -62.070% in the last 3 months …

Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates

Oculis Holding AG (OCS) reported a narrower-than-expected Q2 loss of $0.2 per share, beating the Zacks Consensus Estimate of a $0.48 loss, and surpassed revenue estimates with $0.39 million. Despite this, the company's shares have fallen 39.6% year-to-date, contrasting with the S&P 500's gain, …

Oculis birtir uppgjör fyrir annan ársfjórðung 2026 og kynnir áfanga í rekstri félagsins

ZUG, Sviss, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Félagið færir nú áherslur sínar yfir á taugaauknlækningar með Privosegtor sem leiðandi þróunarlyf félagsins á síðari stigum klínískrar þróunar í gegnum PIONEER-áætlunina. Í kjölfar jákvæðs pre-IND fundar við Matvæla- og lyfjaeftirlit Bandaríkjanna (FDA), eru möguleikar á …

Oculis Reports Q2 2026 Financial Results and Provides Company Update

Oculis, a global biopharmaceutical company, announced its Q2 2026 financial results, reporting $282.3 million in cash, cash equivalents, and short-term investments, providing a cash runway into the second half of 2029. The company is advancing its neuro-ophthalmology pivot with Privosegtor as a lead late-stage …

Here's What Analysts Are Forecasting For Ocular Therapeutix, Inc. (NASDAQ:OCUL) After Its Second-Quarter Results

Ocular Therapeutix (NASDAQ:OCUL) recently released strong second-quarter results, beating revenue expectations and posting smaller-than-anticipated statutory losses. Analysts have slightly increased their optimism regarding per-share losses for 2026, though revenue forecasts remain unchanged. Despite this, the consensus price target of US$27.09 has not shifted, and …

HC Wainwright Has Negative Estimate for OCUL Q3 Earnings

Precision Trading with Oculis Holding Ag (OCS) Risk Zones

Oculis Holding Ag (OCS) shows divergent sentiment across different time horizons, suggesting choppy conditions with elevated downside risk. The article provides institutional trading strategies including long, momentum breakout, and short strategies, along with a multi-timeframe signal analysis detailing support and resistance levels. It emphasizes …

Ocular Therapeutix reports Q2 2026: $13.5M revenue, $78.8M net loss, $598.6M cash

Ocular Therapeutix announced its second-quarter 2026 results, reporting $13.5 million in product revenue, a net loss of $78.8 million, and a strong cash position of $598.6 million. The company is advancing AXPAXLI for wet AMD, with an NDA submission planned for Q4 2026, supported …

Ocular Therapeutix Reports Second Quarter Revenue, Provides Business Highlights

Ocular Therapeutix reported flat second-quarter 2026 revenue of $13.5 million compared to the previous year, alongside an increased net loss of $78.8 million. The company is advancing its investigational drug Axpaxli for wet AMD, with plans to submit an NDA in Q4 2026, and …

Ocular Therapeutix (OCUL) Stock Faces Axpaxli Hopes Against Deepening Losses

Ocular Therapeutix (OCUL) saw a modest 3% stock increase after Q2 2026 earnings, which showed flat revenue and widened net losses, keeping the focus on long-term growth and its pipeline. The company's bullish case hinges on Axpaxli, its wet AMD therapy, showing strong clinical …

Ocular Therapeutix (NASDAQ:OCUL) Beats Expectations in Strong Q2 CY2026

Ocular Therapeutix (NASDAQ:OCUL) reported Q2 CY2026 results, beating Wall Street's revenue expectations with $13.48 million, though sales were flat year-on-year. The company's GAAP loss of $0.35 per share was an 11.2% improvement over analyst estimates. Despite ongoing high expenses and a negative operating margin, …

Ocular estimates AXPAXLI treatment burden up to 72% below projected aflibercept

Ocular Therapeutix reported its Q2 2026 financial results, including $13.5 million in net revenue and a net loss of $78.8 million. The company plans to submit a New Drug Application (NDA) for AXPAXLI for wet AMD in Q4 2026, leveraging the 505(b)(2) pathway to …

Ocular Therapeutix Inc earnings beat by $0.03, revenue topped estimates

Ocular Therapeutix Inc (NASDAQ: OCUL) reported Q2 EPS of $-0.35, beating analyst estimates by $0.03, and revenue of $13.48M, surpassing the consensus of $13.2M. Despite the earnings beat, the company's stock price has declined by 15.86% in the last three months and 33.85% over …

Ocular Therapeutix Releases Q2 2026 Financial Results

Ocular Therapeutix, Inc. reported a net loss of $78.8 million in Q2 2026, though its per-share loss narrowed to -$0.35 from -$0.39 year-over-year. The biopharmaceutical company generated $13.5 million in revenue, a slight increase of 0.1% from Q2 2025, primarily from DEXTENZA product sales. …

Oculis Announces FDA Pre-IND Feedback Regarding Privosegtors Clinical Development Plan

(RTTNews) - Oculis Holding AG (OCS) announced positive FDA pre-IND feedback regarding Privosegtors clinical development plan in acute multiple sclerosis relapses. The FDA Division of Neurology provided positive feedback supporting a regulatory pathway for Privosegtor in acute multiple sclerosis relapses. The FDA confirmed that …

FDA Says Oculis Can Cross-Reference Data for Planned MS Relapse Trial

Oculis (OCS) received positive pre-IND feedback from the U.S. FDA regarding its development strategy for Privosegtor in treating acute multiple sclerosis (MS) relapses. The FDA confirmed that existing data can be cross-referenced, eliminating the need for additional preclinical studies, and supported the proposed clinical …

Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates

Ocular Therapeutix (OCUL) reported a Q2 loss of $0.35 per share, surpassing the Zacks Consensus Estimate of a $0.4 loss and beating revenue estimates with $13.48 million. Despite this, the company's shares have fallen 32.7% year-to-date, and its current Zacks Rank of #5 (Strong …

Oculis Receives Positive FDA Feedback Supporting Development Pathway for Privosegtor in Acute Multiple Sclerosis Relapses

Oculis Holding AG has received positive FDA feedback for its neuroprotective drug Privosegtor, supporting its regulatory pathway for treating acute multiple sclerosis (MS) relapses. The FDA confirmed that existing data from the Phase 2 ACUITY study can be used for a new Investigational New …

Earnings Flash (OCUL) Ocular Therapeutix, Inc. Reports Q2 Revenue $13.5M, vs. FactSet Est of $13.2M

Ocular Therapeutix, Inc. (OCUL) announced its Q2 revenue reached $13.5 million, surpassing FactSet's estimate of $13.2 million. This financial update indicates that the company's revenue performance exceeded analyst expectations for the second quarter. The company also reported a widening net loss and flat revenue …

Ocular Therapeutix (NASDAQ:OCUL) Posts Earnings Results, Beats Estimates By $0.05 EPS

OCULAR THERAPEUTIX, INC Quarterly Earnings Report

Ocular Therapeutix, Inc. Revenue Breakdown – NASDAQ:OCUL

Oculis (OCS) to Release Quarterly Earnings on Thursday

Ocular Therapeutix Inc (OCUL) Financial Health: Profitability & Balance Sheet Analysis

Ocular Therapeutix Inc (OCUL) has a financial score of 6.34, placing it 140 out of 155 in the Pharmaceuticals industry, indicating robust financial status but low operating efficiency. The company reported a Q1 revenue of $10.79M, a 0.81% year-over-year increase, and net profit surged …

Oculis Holding AG Revenue Breakdown – NASDAQ:OCSAW

Oculis Holding AG (NASDAQ: OCSAW) generated $1.51 million USD in revenue last year. The "Innovative Drug" segment was the top-performing segment, contributing $1.44 million USD, which represents an increase from $778.95K USD in the previous year. This indicates a significant revenue stream from its …

What Ocular Therapeutix (OCUL)'s Flat Quarter and AXPAXLI Trial Progress Means For Shareholders

Ocular Therapeutix reported flat first-quarter revenue and missed analyst expectations, leading to a 13% stock drop. However, the company's CEO highlighted encouraging advancements in the AXPAXLI phase 3 trial for wet age-related macular degeneration. The investment narrative largely hinges on AXPAXLI's regulatory path, with …

Insiders At Oculis Holding Sold CHF1.0m In Stock, Alluding To Potential Weakness

Oculis Holding AG saw insiders offload CHF1.0m worth of stock over the past year, although a significant portion of these sales occurred at prices above the current market value. While long-term insider selling might raise concerns, recent insider buying totaling US$139k suggests some confidence …

Ocular Therapeutix (OCUL) Projected to Post Quarterly Earnings on Tuesday

Pharmaceuticals Stocks Q1 In Review: Ocular Therapeutix (NASDAQ:OCUL) Vs Peers

OCS|Oculis Holding AG|Price:11.000|Chg%:-0.020

This article provides a detailed financial overview and market trends for Oculis Holding AG (OCS), a biotechnology company focused on eye disease treatments. It includes real-time stock quotes, key financial figures, analyst ratings indicating a "Strong Buy" with significant upside potential, and technical indicators …

Oculis Holding AG (OCS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article discusses the revenue breakdown of Oculis Holding AG (OCS), noting that relevant data regarding business segments, regional revenue, and profit contributions have not yet been disclosed by the company. Despite the lack of detailed financial segments, the page provides current stock information, …

Oculis Holding AG (OCS) Earnings Forecast: Future EPS & Revenue Growth Estimates

Oculis Holding AG (OCS) has received a "Strong Buy" rating from 12 analysts, with a target price of $39.80, representing a potential upside of 257.59%. The company's expected revenue for the next quarter is $235.59K, and its EPS for the previous quarter was -$0.53, …

Ocular Therapeutix Inc (OCUL) Cash Flow

This article provides a detailed historical cash flow statement for Ocular Therapeutix Inc (OCUL), covering annual and quarterly data from FY2013Q1 to FY2026Q1 across operating, investing, and financing activities. It also includes frequently asked questions defining key cash flow metrics and highlighting OCUL's recent …

Ocular Therapeutix Inc (OCUL) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Ocular Therapeutix Inc (OCUL)'s dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years, indicating no recent dividend payouts or stock splits for the company, and provides current …

Oculis Holding AG (OCS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Oculis Holding AG (OCS), including its support, resistance, indicators, and moving averages. It details various technical indicators like MACD, RSI, and Stochastics, and their current values and directions (e.g., Sell, Neutral, Oversold). The analysis also presents moving …